Over 100 patients were screened and 32 participants (16 placebo group, 16 gabapentin group) were enrolled. Demographics including age, parity, Charlson Comorbidity Index, prior abdominal surgeries, prolapse stage, and baseline rate of bother by validated PFDI-20 and PFIQ-7 surveys did not differ by treatment group. The median change in SPS score from pre-operative baseline scores and 2-week post-operative scores in the placebo and gabapentin treatment groups at rest were 0 (-0.5, -1.0) vs 0 (-1.0, 1.0), p = 0.88, respectively; during normal activity was 0 (-1.5, 1.0) vs 0 (-1.0, 0.5), p = 0.60 respectively; and worst pain 0 (-3.0, 2.5) vs 0 (-1.5, 1.0), p = 0.94 respectively. Incidentally, there was a higher incidence for nausea, vomiting, and diarrhea side effects in the placebo group (20%) vs gabapentin group (0%), p=0.07. Median MME usage per day was 4.3 vs 1.7 in placebo vs gabapentin treatment group respectively, p = 0.14. Validated questionnaires showed overall statistically significant improvement in pelvic floor symptoms in both groups.